ENTITY

Mirxes (2629 HK)

32
Analysis
Health Care • Singapore
Mirxes is a Singapore-headquartered micro ribonucleic acid (miRNA) technology company that develops diagnostic solutions for the early detection of diseases, including cancer, cardiovascular, metabolic, and infectious diseases. Its key products include GASTROClear, a blood-based test for gastric cancer screening, and LUNGClear for lung cancer screening, along with Fortitude COVID-19 RT-qPCR test kits. The company was founded in 2014.
more
bullish•Mirxes
•03 Aug 2023 15:00•Syndicated

Mirxes Lands US$50M to Take Its Cancer Early Detection Solutions to New Markets

Mirxes will use the capital to scale the adoption and penetration of its stomach cancer blood test, GASTROClear, in major APAC markets

Logo
e27
438 Views
Share
x